SynthesisBMC cardiovascular disorders2026
The role of lipid lowering medications in the primary prevention of cardiovascular disease and mortality: a meta-analysis of randomized controlled trials.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceThe mortality benefit of lipid-lowering therapies (LLTs) in true primary prevention of cardiovascular disease (CVD) remains uncertain, in part because prior studies frequently included individuals with existing cardiovascular, vascular, or cerebrovascular disease.
objectiveTo evaluate the effect of LLTs on all-cause mortality and major adverse cardiovascular events exclusively in patients without prior CVD. DATA SOURCES: MEDLINE, EMBASE, and COCHRANE were searched through October 2024 for randomized controlled trials (RCTs) comparing LLTs with control therapy. STUDY SELECTION: RCTs assessing LLTs for primary prevention and reporting mortality or cardiovascular outcomes were included; trials with any participants with prior CVD, vascular disease, or cerebrovascular events were excluded.
resultsTen RCTs including 85,829 participants, met criteria. LLTs did not reduce all-cause mortality compared with control (3.9% vs. 3.9%; RR 0.98, 95% CI 0.89–1.07) or cardiac mortality (1.4% vs. 1.5%; RR 0.92, 95% CI 0.82–1.04). However, LLTs—primarily statins—reduced MACE (RR 0.76, 95% CI 0.68–0.84), myocardial infarction (RR 0.64, 95% CI 0.57–0.72), revascularization (RR 0.70, 95% CI 0.57–0.86), stroke/TIA (RR 0.75, 95% CI 0.57–0.98), and cardiovascular hospitalizations (RR 0.75, 95% CI 0.65–0.87).
conclusionAmong individuals without prior cardiovascular, vascular, or cerebrovascular disease, LLTs did not reduce all-cause or cardiovascular mortality but were associated with significant reductions in nonfatal cardiovascular events. Additional research is needed to define the benefits of LLTs in true primary prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.